Duodenal Ulcer
Gastrointestinal 0 original drugsGastrointestinal indication. Duodenal Ulcer has 0 FDA-approved novel treatments across 6 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Phase 3 Readouts Pro
2 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Duodenal Ulcer Treatments by Mechanism
Top 2 mechanisms across 2 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Duodenal Ulcer Clinical Pipeline by Phase
50 industry-sponsored trials across 21 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Duodenal Ulcer
Novel Duodenal Ulcer Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (7 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Duodenal Ulcer Drug Targets
Molecular targets of approved and investigational Duodenal Ulcer drugs — 6 targets tracked.
Generic Drugs (8 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs